Table 1 Patient characteristics – All patients and by CD34+ dose group.

From: Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

  

CD34+ dose group

 

Measure

All

≤2.5 × 106 cells/kg

>2.5 × 106 cells/kg

p-value

(N = 2479)

(N = 95)

(N = 2384)

Gender, n (%)

   

0.24

 Female

1019 (41)

45 (47)

974 (41)

 

 Male

1460 (59)

50 (53)

1410 (59)

 

Race, n (%)

   

0.13

 Black

445 (18)

11 (12)

434 (19)

 

 Non-Black

1989 (82)

82 (88)

1907 (81)

 

 Unknown

45

2

43

 

Age at auto-HCT (years)

   

0.013

 Median (range)

61 (25–83)

63 (32–78)

61 (25–83)

 

Year of auto-HCT, n (%)

   

0.047

 <2010

487 (20)

11 (12)

476 (20)

 

 ≥2010

1992 (80)

84 (88)

1908 (80)

 

R-ISS, n (%)

   

0.002

 I

567 (35)

12 (19)

555 (36)

 

 II

895 (56)

40 (63)

855 (55)

 

 III

150 (9)

12 (19)

138 (9)

 

 Unknown

867

31

836

 

Light chain type, n (%)

   

0.33

 Kappa

1620 (66)

59 (63)

1561 (66)

 

 Lambda

834 (34)

34 (36)

800 (34)

 

 Biclonal

11 (<1)

1 (1)

10 (<1)

 

 Unknown

14

1

13

 

Cytogenetic risk, n (%)

   

0.32

 Standard

1704 (74)

59 (69)

1645 (74)

 

 High

597 (26)

26 (31)

571 (26)

 

 Unknown

178

10

168

 

LDH, n (%)

   

0.72

 Normal

1360 (83)

49 (82)

1311 (83)

 

 >ULN

272 (17)

11 (18)

261 (17)

 

 Unknown

847

35

812

 

Creatinine

   

0.07

 ≤2

1964 (85)

70 (78)

1894 (85)

 

 >2

359 (15)

20 (22)

339 (15)

 

 Unknown

156

5

151

 

HCT-Cl, n %

   

0.47

 ≤3

1875 (76)

69 (73)

1806 (76)

 

 >3

601 (24)

26 (27)

575 (24)

 

 Unknown

3

0

3

 

Chemotherapy-mobilization

   

0.52

 No

2030 (87)

83 (90)

1947 (87)

 

 Yes

293 (13)

9 (10)

284 (13)

 

 Unknown

156

3

153

 

Plerixafor use

   

<0.001

 No

1475 (64)

36 (40)

1439 (65)

 

 Yes

843 (36)

55 (60)

788 (35)

 

 Unknown

161

4

157

 

Infused CD34+ count

   

<0.001

 Median (range)

4.1 (0.6–26.6)

2.3 (0.6–2.5)

4.2 (2.5–26.6)

 

 Mean

4.5

2.2

4.6

 

Induction regimens, n %

 KRD

364 (15)

17 (18)

347 (15)

0.37

 ImiD+Dexa

340 (14)

10 (11)

330 (14)

0.45

 VTD

104 (4)

5 (5)

99 (4)

0.60

 VCD

301 (12)

11 (12)

290 (12)

1.00

 VD

335 (14)

10 (11)

325 (14)

0.45

 VRD

763 (31)

27 (28)

736 (31)

0.65

 Missing/Other

2

0

2

 

Conditioning regimen, n (%)

   

0.014

 Mel

2023 (82)

84 (88)

1939 (81)

 

 Bu/Mel based

309 (12)

11 (12)

298 (13)

 

 Other

147 (6)

0

147 (6)

 

Response prior to auto-HCT, n (%)

 CR/sCR

329 (13)

16 (17)

313 (13)

0.28

 VGPR

1065 (43)

40 (42)

1025 (43)

0.92

 PR

1022 (41)

38 (40)

984 (41)

0.83

 SD

62 (3)

1 (1)

61 (3)

0.73

 PD

1 (<1)

0

1 (<1)

-

MRD status prior to auto-HCT, n (%)

   

0.32

 Negative

669 (42)

33 (48)

636 (42)

 

 Positive

925 (58)

36 (52)

889 (58)

 

 Not done/unknown

885

26

859

 

Any maintenance, n (%)

   

0.25

 Yes

1762 (71)

73 (77)

1689 (71)

 

 No

717 (29)

22 (23)

695 (29)

 

Maintenance therapy, n (%)

   

0.20

 Rev ± Dexa

1347 (77)

51 (70)

1296 (77)

 

 Non-Reva

314 (18)

16 (22)

298 (18)

 

 Rev/Elo

87 (5)

6 (8)

81 (5)

 
  1. auto-HCT autologous hematopoietic stem cell transplant, Bu/Mel busulfan, melphalan, CR complete response, Dexa dexamethasone, Elo elotuzumab, HCT-CI hematopoietic cell transplantation-specific comorbidity index, ImiD immunomodulatory drug, KRD carfilzomib, lenalidomide, dexamethasone, LDH lactate dehydrogenase, Mel melphalan, MRD minimal residual disease, n number, PR partial response, R-ISS Revised International Staging Systems, Rev lenalidomide, sCR stringent complete response, SD stable disease, ULN upper limit of normal, VCD bortezomib, cyclophosphamide, dexamethasone, VD bortezomib, dexamethasone, VGPR very good partial response, VRD bortezomib, lenalidomide, dexamethasone, VTD bortezomib, thalidomide, dexamethasone.
  2. aIncludes: Dara alone or in combination (n = 19); Thalidomide or pomalidomide, with or without Dexa (n = 64); thalidomide or pomalidomide +PI (88); interferon-based (n = 1); PI with or without Dexa (n = 142).
Back to article page